Drug

SPU-16

CNS Homing Peptide

Market Opportunity

Multiple Sclerosis (MS)

  • There are approximately 400,000 Americans and 2.5 million people worldwide with MS
  • The most widespread disabling neurological condition of young adults
  • Global market for MS drugs expected to reach $38.9 billion by 2032

Technology

  • Licensed from University of Maryland Baltimore
  • Patent issued
  • Central nervous system-homing peptides
  • Use for investigation and treatment of MS and other neuroinflammatory pathology
Previous Drug
Next Drug

Regulatory Pathway & Results 505(b)(2) Pathway

  • May be used as a delivery tool to target current therapies to detect inflammation in the spinal cord
  • May be used for diagnosing and monitoring MS
  • Decreases toxicity of existing therapeutics
  • Animal study results show much improved delivery of therapeutics and decreased toxicity.

Get more information on Silo Pharma. Sign up for email alerts online.

SIGN UP